Early on, appetite is reduced and fatigue can be higher
These sites may offer compounded versions at a discounted price, but the safety of these medications is uncertain as each GLP-1 receptor agonist is only available as a branded medication manufactured by a single company
Now, many patients on GLP-1s experience reduced appetite and early satiety, which can lead to smaller portions, less interest in multiple courses, and sometimes skipping certain dishes altogether. This looks different for every family
You will see the most significant improvements in your blood glucose levels, like your A1c, after two to three months of consistent daily use as prescribed by your doctor
A diagnosis of DKD should be made if repeat testing confirms an elevated albumin to creatinine ratio (greater than 2.5 mg/mmol in men or greater than 3.5 mg/mmol in women) or an eGFR less than 60 mL/min/1.73 m 2
Specifically, the company states that FDA-approved GLP-1/GIP medications for weight loss and type 2 diabetes, including Ozempic, Wegovy, Zepbound, and Mounjaro, "may also be eligible for coverage." The company further states that while they "assist with prior authorizations and prescription submissions," they "do not bill insurance directly." This distinction is important: the compounded GLP-1 program itself is described as a cash-pay arrangement, but the company also facilitates access to FDA-approved branded medications that may have insurance pathways
.jpg)
.webp)
